ProfileGDS5678 / 1437853_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 86% 86% 82% 86% 86% 88% 86% 88% 87% 83% 85% 87% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.8509388
GSM967853U87-EV human glioblastoma xenograft - Control 26.501786
GSM967854U87-EV human glioblastoma xenograft - Control 36.484286
GSM967855U87-EV human glioblastoma xenograft - Control 46.1138782
GSM967856U87-EV human glioblastoma xenograft - Control 56.5439286
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3552286
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7054188
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.466286
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8724288
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6622987
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.0736183
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4907385
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.7568887
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.3523485